Literature DB >> 27053975

Novel Therapies in Development for Metastatic Colorectal Cancer.

Michael S Lee1, Scott Kopetz2.   

Abstract

Colorectal cancer (CRC) is the second most common cause of cancer mortality in the United States. Despite advances in therapy, metastatic CRC remains lethal, and further improvements in therapy are needed. Growing understanding of cancer biology, particularly in growth factor signaling, angiogenesis, and cancer immunology, has translated into many novel therapies under investigation. Patients are increasingly selected for clinical trials rationally on the basis of integral biomarkers. This review discusses several promising agents in development for metastatic CRC.

Entities:  

Year:  2014        PMID： 27053975      PMCID： PMC4812839     

Source DB:  PubMed          Journal:  Gastrointest Cancer Res        ISSN： 1934-7820


  57 in total

1.  Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy.

Authors:  Scott Kopetz; George J Chang; Michael J Overman; Cathy Eng; Daniel J Sargent; David W Larson; Axel Grothey; Jean-Nicolas Vauthey; David M Nagorney; Robert R McWilliams
Journal:  J Clin Oncol       Date:  2009-05-26       Impact factor: 44.544

2.  EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib.

Authors:  Ryan B Corcoran; Hiromichi Ebi; Alexa B Turke; Erin M Coffee; Michiya Nishino; Alexandria P Cogdill; Ronald D Brown; Patricia Della Pelle; Dora Dias-Santagata; Kenneth E Hung; Keith T Flaherty; Adriano Piris; Jennifer A Wargo; Jeffrey Settleman; Mari Mino-Kenudson; Jeffrey A Engelman
Journal:  Cancer Discov       Date:  2012-01-16       Impact factor: 39.397

3.  Efficacy and safety of bevacizumab in metastatic colorectal cancer: pooled analysis from seven randomized controlled trials.

Authors:  Herbert I Hurwitz; Niall C Tebbutt; Fairooz Kabbinavar; Bruce J Giantonio; Zhong-Zhen Guan; Lada Mitchell; Daniel Waterkamp; Josep Tabernero
Journal:  Oncologist       Date:  2013-07-23

4.  Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates.

Authors:  Julie R Brahmer; Charles G Drake; Ira Wollner; John D Powderly; Joel Picus; William H Sharfman; Elizabeth Stankevich; Alice Pons; Theresa M Salay; Tracee L McMiller; Marta M Gilson; Changyu Wang; Mark Selby; Janis M Taube; Robert Anders; Lieping Chen; Alan J Korman; Drew M Pardoll; Israel Lowy; Suzanne L Topalian
Journal:  J Clin Oncol       Date:  2010-06-01       Impact factor: 44.544

5.  Blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer.

Authors:  Sandra Misale; Sabrina Arena; Simona Lamba; Giulia Siravegna; Alice Lallo; Sebastijan Hobor; Mariangela Russo; Michela Buscarino; Luca Lazzari; Andrea Sartore-Bianchi; Katia Bencardino; Alessio Amatu; Calogero Lauricella; Emanuele Valtorta; Salvatore Siena; Federica Di Nicolantonio; Alberto Bardelli
Journal:  Sci Transl Med       Date:  2014-02-19       Impact factor: 17.956

6.  Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance.

Authors:  Scott Kopetz; Paulo M Hoff; Jeffrey S Morris; Robert A Wolff; Cathy Eng; Katrina Y Glover; Rosie Adinin; Michael J Overman; Vincete Valero; Sijin Wen; Christopher Lieu; Shaoyu Yan; Hai T Tran; Lee M Ellis; James L Abbruzzese; John V Heymach
Journal:  J Clin Oncol       Date:  2009-12-14       Impact factor: 44.544

7.  High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practice.

Authors:  Daniele Santini; Fotios Loupakis; Bruno Vincenzi; Irene Floriani; Irene Stasi; Emanuele Canestrari; Eliana Rulli; Paolo Enrico Maltese; Francesca Andreoni; Gianluca Masi; Francesco Graziano; Giacomo Giulio Baldi; Lisa Salvatore; Antonio Russo; Giuseppe Perrone; Maria Rosa Tommasino; Mauro Magnani; Alfredo Falcone; Giuseppe Tonini; Annamaria Ruzzo
Journal:  Oncologist       Date:  2008-12-04

8.  Tumor-infiltrating lymphocytes in colorectal cancers with microsatellite instability are correlated with the number and spectrum of frameshift mutations.

Authors:  David Tougeron; Emilie Fauquembergue; Alexandre Rouquette; Florence Le Pessot; Richard Sesboüé; Michèle Laurent; Pascaline Berthet; Jacques Mauillon; Frédéric Di Fiore; Jean-Christophe Sabourin; Pierre Michel; Mario Tosi; Thierry Frébourg; Jean-Baptiste Latouche
Journal:  Mod Pathol       Date:  2009-06-05       Impact factor: 7.842

9.  Nivolumab plus ipilimumab in advanced melanoma.

Authors:  Jedd D Wolchok; Harriet Kluger; Margaret K Callahan; Michael A Postow; Naiyer A Rizvi; Alexander M Lesokhin; Neil H Segal; Charlotte E Ariyan; Ruth-Ann Gordon; Kathleen Reed; Matthew M Burke; Anne Caldwell; Stephanie A Kronenberg; Blessing U Agunwamba; Xiaoling Zhang; Israel Lowy; Hector David Inzunza; William Feely; Christine E Horak; Quan Hong; Alan J Korman; Jon M Wigginton; Ashok Gupta; Mario Sznol
Journal:  N Engl J Med       Date:  2013-06-02       Impact factor: 91.245

10.  Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial.

Authors:  Axel Grothey; Eric Van Cutsem; Alberto Sobrero; Salvatore Siena; Alfredo Falcone; Marc Ychou; Yves Humblet; Olivier Bouché; Laurent Mineur; Carlo Barone; Antoine Adenis; Josep Tabernero; Takayuki Yoshino; Heinz-Josef Lenz; Richard M Goldberg; Daniel J Sargent; Frank Cihon; Lisa Cupit; Andrea Wagner; Dirk Laurent
Journal:  Lancet       Date:  2012-11-22       Impact factor: 79.321
View more
  3 in total

1.  Advanced cancer patients in a randomized clinical trial of night-simulating eyeglasses observed to have a normal 24-h circadian rhythm during chemotherapy.

Authors:  Keith I Block; Charlotte Gyllenhaal; James F Grutsch; Penny B Block; Thomas Kazlausky; David Blask; Edward Carome; Justin Reynolds; Dinah Faith Q Huff; William Hrushesky
Journal:  SAGE Open Med       Date:  2022-05-23

2.  Mutant KRAS promotes liver metastasis of colorectal cancer, in part, by upregulating the MEK-Sp1-DNMT1-miR-137-YB-1-IGF-IR signaling pathway.

Authors:  Po-Chen Chu; Peng-Chan Lin; Hsing-Yu Wu; Kuen-Tyng Lin; Christina Wu; Tanios Bekaii-Saab; Yih-Jyh Lin; Chung-Ta Lee; Jeng-Chang Lee; Ching-Shih Chen
Journal:  Oncogene       Date:  2018-03-21       Impact factor: 9.867

Review 3.  Multifunctional nanomedicines for targeting epidermal growth factor receptor in colorectal cancer.

Authors:  Mostafa Akbarzadeh Khiavi; Azam Safary; Jaleh Barar; Amir Ajoolabady; Mohammad Hossein Somi; Yadollah Omidi
Journal:  Cell Mol Life Sci       Date:  2019-09-28       Impact factor: 9.261
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.